Duke John D 4

What Happened

• John D. Duke, Chief Executive Officer of Harvard Bioscience (HBIO), reported an award of 75,000 restricted stock units (RSUs) on 2026-03-20. The reported acquisition price is $0.00 (typical for RSU grants).
• The filing’s remarks also disclose (separately) a March 16, 2026 purchase of 5,000 shares, an additional time‑vested award of 50,000 RSUs (vesting in three equal installments beginning August 8, 2026), and a 50,000 RSU performance‑based award tied to relative total shareholder return vs. the Russell 2000 (target shown; max payout 150%).

Key Details

• Transaction date and type: 2026-03-20 — Award/Grant (code A) of 75,000 RSUs at $0.00.
• Vesting for the 75,000 RSUs: three equal installments on March 20 of 2027, 2028 and 2029, per the award agreement.
• Additional items disclosed in remarks: 5,000 shares purchased on 2026-03-16; 50,000 time‑vested RSUs (3 equal installments starting 8/8/2026); 50,000 performance RSUs with relative TSR metrics (performance period Aug 8, 2025 to earlier of July 30, 2028 or change of control); reported target for performance RSUs with max 150%.
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Filing date: Form 4 filed 2026-03-23 (3 days after the primary transaction date); the filing does not include a late‑filing flag in the provided information.

Context

• RSUs are grants that convert to shares only after vesting and any applicable conditions are met; the $0.00 price reflects a grant rather than an open‑market purchase.
• The performance RSUs depend on relative TSR versus the Russell 2000 and could pay up to 150% of the target number if performance criteria are met.
• The separate 5,000‑share purchase reported in the remarks is an actual stock purchase (direct ownership), while the RSUs are future compensation subject to vesting and performance conditions.